ITM Isotope Technologies Munich SE(ITM), a radiopharmaceutical biotech company, announced that it has executed its license agreement with the life science business of Merck KGaA, Darmstadt, Germany, to obtain a worldwide exclusive license for the clinical development and commercialization of radiolabeled folate derivatives for therapeutic and diagnostic applications against folate-receptor-positive malignant tumors. Under the terms of the agreement, the company will supply ITM with its first-in-class folate precursors for radiolabeling, which ITM will use to advance the clinical and potential future commercial development of its folate receptor-targeting radiopharmaceutical pipeline candidates.
To read more please visit:
Source: ITM